BackgroundExtracorporeal membrane oxygenation (ECMO), has partly improved congenital diaphragmatic hernia (CDH) outcomes, yet the overall morbidity and mortality remain high. Existing prenatal indicators for CDH fetuses are operator‐dependent, time‐consuming, or less accurate, a new simple and accurate indicator to indicate adverse events in CDH patients is needed.PurposeTo propose and assess the association of a new MRI parameter, the relative mediastinal displacement index (RMDI), with adverse events including in‐hospital deaths or the need for ECMO in fetuses with isolated left CDH (iLCDH).Study TypeRetrospective analysis.SubjectsOne hundred thirty‐nine fetuses were included in the iLCDH group (24 with adverse events and 115 without) and 257 fetuses were included in the control group from two centers in Guangzhou.Field Strength/Sequence3.0 T, T2WI‐TRUFI; 1.5 T, T2WI‐FIESTA.AssessmentThree operators independently measured the , , and DH on the axial images. The calculation formula of the RMDI was ( + )/DH.Statistical TestsThe independent sample t test, Mann–Whitney U test, Chi‐square test, Chi‐square test continuity correction, Fisher's test, linear regression analysis, logistic regression analysis, intraclass correlation coefficient, receiver operating characteristic curve analysis, and Delong test. A P value <0.05 was considered statistically significant.ResultsThe RMDI did not change with gestational age in the iLCDH group (with [P = 0.189] and without [P = 0.567] adverse events) and the control group (P = 0.876). There were significant differences in RMDI between the iLCDH group (0.89 [0.65, 1.00]) and the control group (−0.23 [−0.34, −0.16]). In the iLCDH group, RMDI was the only indicator left for indicating adverse events, and the best cutoff value was 1.105. Moreover, there was a significant difference in diagnostic accuracy between the RMDI (AUC = 0.900) and MSA (AUC = 0.820), LHR (AUC = 0.753), o/e LHR (AUC = 0.709), and o/e TFLV (AUC = 0.728), respectively.Data ConclusionThe RMDI is expected to be a simple and accurate tool for indicating adverse events in fetuses with iLCDH.Evidence Level4Technical EfficacyStage 1